CA2925935A1 - Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis - Google Patents

Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis Download PDF

Info

Publication number
CA2925935A1
CA2925935A1 CA2925935A CA2925935A CA2925935A1 CA 2925935 A1 CA2925935 A1 CA 2925935A1 CA 2925935 A CA2925935 A CA 2925935A CA 2925935 A CA2925935 A CA 2925935A CA 2925935 A1 CA2925935 A1 CA 2925935A1
Authority
CA
Canada
Prior art keywords
compound
amino
treatment
present
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2925935A
Other languages
English (en)
French (fr)
Inventor
Toru Kawamura
Yasushi Fujitani
Masayuki Takizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA2925935A1 publication Critical patent/CA2925935A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2925935A 2013-10-03 2014-10-02 Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis Abandoned CA2925935A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361886403P 2013-10-03 2013-10-03
US61/886,403 2013-10-03
PCT/US2014/058738 WO2015051067A1 (en) 2013-10-03 2014-10-02 Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis

Publications (1)

Publication Number Publication Date
CA2925935A1 true CA2925935A1 (en) 2015-04-09

Family

ID=51842818

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2925935A Abandoned CA2925935A1 (en) 2013-10-03 2014-10-02 Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis

Country Status (10)

Country Link
US (2) US20160250238A1 (enExample)
EP (1) EP3052105A1 (enExample)
JP (1) JP2016531886A (enExample)
KR (1) KR20160058886A (enExample)
CN (1) CN105705149A (enExample)
BR (1) BR112016007237A2 (enExample)
CA (1) CA2925935A1 (enExample)
EA (1) EA201690686A1 (enExample)
MX (1) MX2016003979A (enExample)
WO (1) WO2015051067A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020000092A1 (en) * 2018-06-27 2020-01-02 Algernon Pharmaceuticals Inc. The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease
CN115515578A (zh) * 2020-05-07 2022-12-23 诺罗瑞韦有限公司 用于治疗抑郁症的环丝氨酸和己酮可可碱联合疗法
CN121041156A (zh) * 2025-08-27 2025-12-02 复皙药业(上海)有限公司 含有替普瑞酮的具有祛红功效的膏霜及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
KR20140042933A (ko) * 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
SI2318419T2 (sl) * 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
WO2012177835A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use

Also Published As

Publication number Publication date
MX2016003979A (es) 2016-06-15
BR112016007237A2 (pt) 2017-09-12
US20180099000A1 (en) 2018-04-12
WO2015051067A1 (en) 2015-04-09
JP2016531886A (ja) 2016-10-13
EP3052105A1 (en) 2016-08-10
KR20160058886A (ko) 2016-05-25
EA201690686A1 (ru) 2016-08-31
CN105705149A (zh) 2016-06-22
US20160250238A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
EP2759533B1 (en) Condensed heterocyclic compound
EP1423376B1 (en) Bicyclic compound, production and use thereof
KR20180080189A (ko) 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물
JPWO2007123186A1 (ja) 医薬
EP1498125A1 (en) Use of compounds having ccr antagonism
AU776851B2 (en) Stable emulsion compositions
US20180099000A1 (en) Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
EP1495756A1 (en) Severe sepsis preventive therapeutic agent
WO2007132825A1 (ja) 医薬
US10738004B2 (en) Cyclic compound
US20060178359A1 (en) Tricyclic compound, process for producing the same, and use
US7288654B2 (en) Fused-ring pyridine derivative, process for producing the same, and use
JP2004002402A (ja) Ccr拮抗作用を有する化合物の用途
CA3036349C (en) Cyclic compound having toll-like receptor 4 (tlr4) inhibitory activity
JP2004002370A (ja) 重症セプシス予防治療剤
JP2002302458A5 (enExample)
EP2039681A1 (en) Cycloalkene derivatives, process for production of the derivatives, and use of the same
US20170105969A1 (en) Cenicriviroc for the treatment of hiv-2 infection
JP2004256529A (ja) 縮環ピリジン誘導体、その製造法および用途

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20191002